Herophilus (herophilus.com): no confident changes recorded yet; website history since July 2021. Homepage last checked 6 November 2026.
First recorded website
Observed 21 July 2021
Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.
How it described itself
Reinventing neuro drug discovery. We are Herophilus. Cures, not correlations.
Herophilus is a San Francisco-based neurotherapeutics company that employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases.
All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.
Recorded changes
Newest observations first. Each interval bounds when the website changed; it is not an exact event date.
No changes recorded yet. Missing observations do not mean the company has not changed.
How it describes itself
Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.
September 2023 – November 2026 · 5 captures · latest observed messagingHerophilus - Cures, not Correlations
We are reinventing neuro drug discovery by combining human brain models, scaled biology and machine learning to systematically discover and develop novel drugs with greater therapeutic potential.
26 September 2023 · Herophilus - Cures, not Correlationsarchived page
8 July 2024 · Herophilus - Cures, not Correlationsarchived page
13 January 2025 · Herophilus - Cures, not Correlationsarchived page
13 January 2026 · Herophilus - Cures, not Correlationsarchived page
6 November 2026 · Herophilus - Cures, not Correlationscurrent websiteHistorical capture not publicly available
July 2021 – February 2023 · 3 capturesReinventing neuro drug discovery.
We are reinventing neuro drug discovery by combining human brain models, scaled biology and machine learning to systematically discover and develop novel drugs with greater therapeutic potential.